Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Verve Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
VERV
Nasdaq
8731
https://www.vervetx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Verve Therapeutics Inc
Verve Therapeutics, Inc. (NASDAQ:VERV) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
- May 11th, 2024 12:53 pm
Analysts Are Betting On Verve Therapeutics, Inc. (NASDAQ:VERV) With A Big Upgrade This Week
- May 10th, 2024 11:06 am
Verve Therapeutics First Quarter 2024 Earnings: Beats Expectations
- May 9th, 2024 10:56 am
Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates
- May 8th, 2024 12:10 pm
Verve Therapeutics Announces Pipeline Progress and Reports First Quarter 2024 Financial Results
- May 8th, 2024 11:00 am
Verve moves forward with backup base editing therapy
- May 7th, 2024 11:20 am
Verve Therapeutics Announces Dosing of First Patient in Heart-2 Phase 1b Clinical Trial Evaluating VERVE-102
- May 7th, 2024 11:00 am
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- May 3rd, 2024 8:01 pm
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
- Apr 25th, 2024 1:00 pm
After a Serious Setback, Is Verve Therapeutics a Buy?
- Apr 6th, 2024 1:50 pm
Biotech Stock Roundup: IRON, VERV Down on Study Updates, BMYs Drug News & More
- Apr 4th, 2024 5:21 pm
Verve (VERV) Pauses Enrollment in Cholesterol Study, Stock Falls
- Apr 3rd, 2024 5:40 pm
Verve Plunges To Record Low After Cholesterol-Lowering Gene Editor Causes Side Effects
- Apr 2nd, 2024 8:04 pm
UPDATE 1-Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
- Apr 2nd, 2024 11:35 am
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
- Apr 2nd, 2024 11:00 am
Verve Therapeutics Announces Updates on its PCSK9 Program
- Apr 2nd, 2024 11:00 am
Verve pauses base editing trial, shifts strategy after treatment side effect
- Apr 2nd, 2024 7:03 am
3 Stocks That Could Be the Next Big Thing in Gene Editing
- Mar 21st, 2024 8:19 pm
New Forecasts: Here's What Analysts Think The Future Holds For Verve Therapeutics, Inc. (NASDAQ:VERV)
- Feb 29th, 2024 11:12 am
Verve Therapeutics Full Year 2023 Earnings: Beats Expectations
- Feb 28th, 2024 11:00 am
Scroll